[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Tanguay C, Harvey I, Houde M, Srigley JR, Têtu B: Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases. Mod Pathol; 2003 May;16(5):512-4
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases.
  • Leiomyosarcoma of urinary bladder is rare, although it is the most common mesenchymal tumor in adults.
  • We report two cases of this tumor following cyclophosphamide therapy.
  • He presented with painless hematuria, and the initial biopsy of the bladder tumor revealed a malignant spindle cell neoplasm.
  • A final diagnosis of leiomyosarcoma was made on radical cystoprostatectomy.
  • He also presented with painless hematuria, and a bladder tumor was resected transurethrally and diagnosed as leiomyosarcoma.
  • Cyclophosphamide, when used for a neoplastic or non-neoplastic condition, is associated with an increased risk of developing bladder cancer.
  • The distribution of histologic subtypes differs from that seen in spontaneous bladder tumors.
  • [MeSH-major] Cyclophosphamide / adverse effects. Immunosuppressive Agents / adverse effects. Leiomyosarcoma / chemically induced. Urinary Bladder Neoplasms / chemically induced
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulomatosis with Polyangiitis / complications. Granulomatosis with Polyangiitis / drug therapy. Humans. Male. Middle Aged. Neoplasms, Second Primary. Retinoblastoma / drug therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12748258.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


2. Kato K, Arai K, Tanaka Y, Ijiri R, Kato Y, Kigasawa H, Toyoda Y, Aida N, Ohama Y: Epithelioid leiomyosarcoma in a non-immunocompromised infant: additional differential diagnosis of pediatric "round cell tumors". Mod Pathol; 2000 Oct;13(10):1156-60
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid leiomyosarcoma in a non-immunocompromised infant: additional differential diagnosis of pediatric "round cell tumors".
  • We report an 18-month-old Japanese girl with purely epithelioid leiomyosarcoma presenting as a huge intraabdominal mass.
  • Silver stain, however, demonstrated well-developed reticulin fibers often outlining individual tumor cells.
  • The diagnosis of epithelioid leiomyosarcoma was made.
  • Following reduction in tumor size by chemotherapy, the serum NSE level was normalized.
  • From the surgical finding, the primary site was presumed to be the urachus or the urinary bladder dome.
  • Although extremely rare, epithelioid leiomyosarcoma should be added in the list of differential diagnoses of pediatric "round cell tumors. "
  • [MeSH-major] Abdominal Neoplasms / pathology. Immunocompromised Host. Leiomyosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Infant. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11048812.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


3. Rassnick KM, Frimberger AE, Wood CA, Williams LE, Cotter SM, Moore AS: Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Intern Med; 2000 May-Jun;14(3):271-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of ifosfamide for treatment of various canine neoplasms.
  • Complete responses were seen in 1 dog with metastatic leiomyosarcoma of the urinary bladder and in 1 dog with metastatic cutaneous hemangiosarcoma.
  • Six dogs with splenic hemangiosarcoma received ifosfamide postsplenectomy and their median survival time was 147 days.
  • No dog developed clinical or microscopic evidence of hemorrhagic cystitis.
  • Ifosfamide appears safe to use in tumor-bearing dogs, and the evaluation of combination chemotherapy protocols that include ifosfamide should be considered.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10830540.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


Advertisement
4. Al-Zahrani AA, Kamal BA, Eldarawani HM, Hashim TM: Leiomyosarcoma of the bladder in a 16-year-old girl with a history of cyclophosphamide therapy for bilateral retinoblastoma during infancy. Saudi Med J; 2006 Apr;27(4):531-3
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the bladder in a 16-year-old girl with a history of cyclophosphamide therapy for bilateral retinoblastoma during infancy.
  • A 16-year-old female with bladder leiomyosarcoma had a history of bilateral retinoblastoma at 6 months of life.
  • She received cyclophosphamide chemotherapy after surgical enucleation.
  • In this report, we discussed the possible role of retinoblastoma or cyclophosphamide as a target for the development of bladder leiomyosarcoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Cyclophosphamide / adverse effects. Leiomyosarcoma / chemically induced. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy. Urinary Bladder Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598333.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


5. Matsumoto S, Shimizu N, Moriguchi N, Yagi M, Uemura H: Bladder leiomyosarcoma in a boy. Int Urol Nephrol; 2006;38(3-4):549-51
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder leiomyosarcoma in a boy.
  • Leiomyosarcoma of the urinary bladder in childhood is uncommon.
  • We reported bladder leiomyosarcoma in a 10-year-old boy.
  • He had underwent the extirpation of the tumor and performed adjuvant chemotherapy in combination with radiotherapy according to the Intergroup Rhabdomyosarcoma Study-4 regimens.
  • [MeSH-major] Leiomyosarcoma / therapy. Urinary Bladder Neoplasms / therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Urology. 2002 Jul;60(1):164 [12100953.001]
  • [Cites] Pediatr Pathol. 1986;6(2-3):181-97 [3822934.001]
  • [Cites] Pathol Oncol Res. 1998;4(4):308-9 [9887363.001]
  • (PMID = 17115292.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. García Torrelles M, Beltrán Armada JR, Rubio Tortosa I, Sánchez Sanchis M, Rodrigo Guanter V, Tarin Planes M, Sanjuán de Laorden C: [Bladder leiomyosarcoma. Case report]. Arch Esp Urol; 2006 Nov;59(9):908-10
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder leiomyosarcoma. Case report].
  • OBJECTIVE: We report a new case of bladder leiomyosarcoma in a young female patient.
  • We review its features and different treatment options.
  • METHODS: The patient underwent neoadyuvant chemotherapy and surgical excision.
  • RESULTS: A partial response was achieved with neoadyuvant chemotherapy and remains still alive 60 moths after radical cystectomy CONCLUSION: Despite the poor prognosis of this disease, multimodal treatment may improve results.
  • Neoadyuvant chemotherapy and subsequent radical excision could be a good combination therapy for these aggressive tumors.
  • [MeSH-major] Leiomyosarcoma. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190216.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 10
  •  go-up   go-down


7. Motta L, Porcaro AB, Ficarra V, D'Amico A, Piubello Q, Comunale L: Leiomyosarcoma of the bladder fourteen years after cyclophosphamide therapy for retinoblastoma. Scand J Urol Nephrol; 2001 Jun;35(3):248-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the bladder fourteen years after cyclophosphamide therapy for retinoblastoma.
  • We report a case of bladder leiomyosarcoma which occurred in a 22-year-old female who had been treated with cyclophosphamide for a period of 68 months for retinoblastoma diagnosed at 18 months postpartum.
  • [MeSH-major] Cyclophosphamide / adverse effects. Leiomyosarcoma / chemically induced. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy. Urinary Bladder Neoplasms / chemically induced
  • [MeSH-minor] Adolescent. Female. Humans. Infant. Time Factors

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11487082.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


8. Rosser CJ, Slaton JW, Izawa JI, Levy LB, Dinney CP: Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology; 2003 Jun;61(6):1151-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults.
  • OBJECTIVES: To determine the clinical presentation and outcome of patients with high-grade bladder leiomyosarcoma.
  • METHODS: Between July 1986 and April 1998, 36 adult patients (mean follow-up 56 months) with a diagnosis of urinary bladder leiomyosarcoma were evaluated at the University of Texas M. D.
  • We retrospectively reviewed the records of these patients for information on clinical features, treatment, and outcome.
  • Thirty-five patients were treated surgically for bladder leiomyosarcoma; of these, 12 (34%) developed recurrent disease (5 with local recurrence and 7 with distant metastasis), with a median time to diagnosis of recurrent disease of 8.3 months.
  • Multivariate analyses demonstrated that only the Memorial Sloan-Kettering Cancer Center disease stage system was a significant predictor of survival of patients with bladder leiomyosarcoma (P = 0.018).
  • CONCLUSIONS: In patients with high-grade leiomyosarcoma of the bladder, radical cystectomy in the face of localized disease, whether at the initial presentation or after neoadjuvant chemotherapy, can result in a 5-year, disease-specific survival rate of 62.0%.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / methods. Cystectomy / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / diagnosis. Retroperitoneal Neoplasms / secondary. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Urology. 2004 Jul;64(1):188 [15245972.001]
  • (PMID = 12809885.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


9. Jaidane M, Slama A, Ben Sorba N, Yacoubi T, Ghammed S, Elleuch A, Mosbah F: [Bladder leiomyosarcoma: report of a case]. Ann Urol (Paris); 2000 Jun;34(3):179-83
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder leiomyosarcoma: report of a case].
  • Leiomyosarcoma of the urinary bladder is an extremely rare disease.
  • In this study, which also includes a review of the literature, a new case of urinary bladder leiomyosarcoma has been reported in a 65-year old male, which was detected during an investigation of total hematuria accompanied by burning upon micturition.
  • The clinical examination was normal, but ultrasonography followed by bladder endoscopy showed the presence of a large bladder tumor.
  • The definitive diagnosis of this type of tumor can only be made after histological and immunohistochemical investigation, and to avoid unnecessary surgery it is essential to first differentiate it from an inflammatory pseudosarcoma.
  • Although in the present study the outcome following total cystoprostatectomy was favorable at 3 months follow-up, in general the prognosis is uncertain due to the potentially invasive character of this type of tumor.
  • Given the limited number of studies on the subject treatment still remains controversial, but is essentially based on surgical excision, possibly with adjuvant chemotherapy.
  • [MeSH-major] Leiomyosarcoma. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10953795.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 22
  •  go-up   go-down


10. Liang SX, Lakshmanan Y, Woda BA, Jiang Z: A high-grade primary leiomyosarcoma of the bladder in a survivor of retinoblastoma. Arch Pathol Lab Med; 2001 Sep;125(9):1231-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A high-grade primary leiomyosarcoma of the bladder in a survivor of retinoblastoma.
  • Osteosarcoma is by far the most common type with an incidence of up to 50%, followed by soft tissue sarcomas.
  • Visceral leiomyosarcoma is extremely rare and only 2 cases have been reported in the past 2 decades, one in the liver and another one in the urinary bladder, both of which developed after cyclophosphamide therapy.
  • Here we report a case of vesical leiomyosarcoma that was diagnosed in a 49-year-old woman 47 years after the diagnosis of a hereditary retinoblastoma.
  • The patient's retinoblastoma was treated with unilateral enucleation without adjuvant radiation or chemotherapy.
  • We believe that this is the first report of vesical leiomyosarcoma occurring in a patient with retinoblastoma without a prior history of radiation or chemotherapy.
  • This report is significant not only because of the rarity of vesical leiomyosarcoma as a second nonocular tumor in retinoblastoma patients, but also because of the infrequency of vesical leiomyosarcoma in general.
  • We also investigated the potential molecular pathogenesis of the leiomyosarcoma.
  • [MeSH-major] Eye Neoplasms / surgery. Leiomyosarcoma / pathology. Neoplasms, Second Primary / pathology. Retinoblastoma / surgery. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Adult. Cyclin D1 / analysis. Cystectomy. Desmin / analysis. Female. Hematuria / etiology. Humans. Hysterectomy. Ovariectomy. Retinoblastoma Protein / analysis. Survivors. Tomography, X-Ray Computed. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11520280.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


11. Sawhney R, Curry N, Burks T, Chaudhary UB: Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel. Anticancer Drugs; 2007 Jul;18(6):745-7
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel.
  • Leiomyosarcoma of the urinary bladder is a rare mesenchymal tumor with distinct pathologic features.
  • Although radical cystectomy is the standard therapy for locally invasive disease, available literature appears to support the benefit of perioperative chemotherapy, similar to that seen with the more conventional urothelial malignancies.
  • We report on a 77-year-old gentleman with locally advanced leiomyosarcoma of the bladder achieving a near-complete pathologic response to neoadjuvant chemotherapy with a unique regimen: gemcitabine and docetaxel.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leiomyosarcoma. Urinary Bladder Neoplasms
  • [MeSH-minor] Aged. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease-Free Survival. Humans. Male. Neoadjuvant Therapy. Neoplasm Invasiveness. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762407.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


12. Parekh DJ, Jung C, O'Conner J, Dutta S, Smith ER Jr: Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. Urology; 2002 Jul;60(1):164
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas.
  • We report an unusual case of a leiomyosarcoma of the urinary bladder after chemotherapy for retinoblastoma and the results of a review of the published reports of bladder sarcomas.
  • A 22-year-old man presented with hematuria and was found to have a mass in his urinary bladder on computed tomography.
  • Transurethral resection of the mass revealed a leiomyosarcoma.
  • The final pathologic examination confirmed high-grade leiomyosarcoma.
  • [MeSH-major] Cyclophosphamide / therapeutic use. Leiomyosarcoma / diagnosis. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cystectomy / methods. Hematuria / diagnosis. Humans. Male. Prognosis. Urinary Diversion / methods

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12100953.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 13
  •  go-up   go-down


13. Murakami M, Tsukada H, Ikeda M, Watanabe M, Muramatsu T, Miyamoto T, Makino T, Yasuda S, Ide M, Nasu S: Availability of whole-body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Availability of whole-body positron emission tomography (PET) for the detection of metastatic sites in recurrent uterine sarcoma.
  • Accurate diagnosis of the metastatic sites is important for the treatment strategy.
  • Unfortunately current diagnostic techniques, including CT, MRI, and ultrasonography (US) are not efficient for the detection of recurrence.
  • There is little report of the experience with whole-body 18 fluorodeoxyglucose (FDG)-PET for the detection of recurrence in the follow up of patients with uterine sarcomas.
  • The purpose of this study is to evaluate the availability of FDG-PET for the detection of recurrence in patients with uterine sarcomas.
  • METHODS: Twelve patients with pathologically proven uterine sarcomas (nine leiomyosarcoma and three carcinosarcoma) took FDG-PET, CT, MRI and US for the purpose of the detection of recurrence after the primary treatment.
  • Post-void static images of PET were obtained in all cases to minimize bladder FDG activity.
  • RESULTS: The final diagnoses of recurrence were established in five cases (three carcinosarcoma and two leiomyosarcoma).
  • Positive results of PET scan did not affect the prognosis in four patients, but another patient with solitary intraperitoneal tumor by PET scan could received the chemotherapy and operation, which histologically confirmed the recurrence of leiomyosarcoma.
  • Application of PET scan for the early detection of recurrence may affect the prognosis of some patients with uterine sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015696.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB: Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol; 2007 Jan-Feb;25(1):38-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of the M.D. Anderson experience in the treatment of bladder sarcoma.
  • OBJECTIVE: To assess the histologic subtypes, clinical presentations, treatment approaches, and treatment-related outcomes of patients with bladder sarcoma.
  • METHODS: Between January 1985 and July 2004, 19 patients (12 men and 7 women) with primary bladder sarcoma were evaluated at the University of Texas M.D.
  • The histologic subtypes of bladder sarcoma were leiomyosarcoma (N = 14), angiosarcoma (N = 3), and unclassified sarcoma (N = 2).
  • The primary treatment modalities used were surgery in 16 (84%) patients, chemotherapy in 2 (11%), and palliation in 1 (5%).
  • The rate of local and distal recurrence was 16% and 53%, respectively.
  • There was no statistically significant difference in disease-specific survival between patients with bladder leiomyosarcoma compared to other sarcoma subtypes (P = 0.149).
  • CONCLUSIONS: Bladder sarcoma is a highly aggressive malignancy, regardless of its histologic subtype.
  • [MeSH-major] Sarcoma / therapy. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17208137.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


15. Anglada Curado FJ, López Beltrán A, Prieto Castro R, Regueiro López JC, Leva Vallejo M, Alameda Aragoneses V, Blanco Espinosa A, Moreno Arcas P, Requena Tapia MJ: [Malignant fibrohistiocytoma of the bladder]. Actas Urol Esp; 2000 Jul-Aug;24(7):581-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant fibrohistiocytoma of the bladder].
  • We result the importance of immunohistochemistry and ultrastructural study to support the diagnosis of malignant fibrous histiocytoma of the urinary bladder.
  • The rarity of vesical localization of this tumour may delay its diagnosis.
  • It must be supported by a immunohistochemistry and/or ultrastructural study, in order to differentiate from other tumours with fibrohistiocytoma-like pattern: leiomyosarcoma and sarcomatoid carcinoma of the bladder.
  • After radical removal of tumour, adjuvant therapy is recommended both systemic chemotherapy and local radiotherapy, although survival rates are over 5.3 months after first therapeutical actuation.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11011450.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


16. Xu AX, Wang XX, Hong BF, Ye LY, Zhang L: [Non-epithelial tissue tumors of the urinary bladder]. Zhonghua Wai Ke Za Zhi; 2003 Jul;41(7):530-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-epithelial tissue tumors of the urinary bladder].
  • OBJECTIVE: To summarize the experience in the diagnosis and treatment of non-epithelial tissue tumor of urinary bladder.
  • METHODS: >From 1953 to April 2002, a total of 28 patients with non-epithelial tissue tumor in 3 925 bladder tumor cases were analyzed.
  • RESULTS: Painless gross hematuria, pelvic mass, urinary frequency and dysuria are symptoms of non-epithelial bladder tumor.
  • Ultrasonic examination, computed tomography (CT) scan, cystoscopy and biopsy is used for diagnosis of the tumor.
  • Seventeen of 28 patients (61.7%) were malignant neoplasms in 7 kinds of pathologic types, which was small cell carcinoma (5 cases), rhabdomyosarcoma (4 cases), leiomyosarcoma (4 cases), lymphoma (1 case), malignant fibrous histiocytoma (1 case), liposarcoma(1 case), melanoma (1 case) respectively.
  • Eleven of 28 patients (39.3%) were benign tumors with 4 kinds of histologic types including 2 cases of cavernous hemangioma, 1 case of fibroma, 1 case of leiomyoma, 7 cases of pheochromocytoma.
  • All benign tumor patients were treated with partial cystectomy, transurethral bladder tumor resect (TURBT) and fulguration.
  • Those malignant bladder tumor patient are followed up, but 3 years survival rates is only 8/17.
  • CONCLUSIONS: Non-epithelial tissue tumor of the urinary bladder is rare with complicated pathologic types.
  • Diagnosis rate which was confirmed before operation is low.
  • Dip biopsy under cystoscopy may enhance the diagnosis rate.
  • Surgical treatment is the main therapy for non-epithelial tissue tumor of the urinary bladder.
  • According to the histologic appearance radiotherapy and chemotherapy is mandatory in some cases.
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cystectomy / methods. Cystoscopy. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Urinary Bladder / pathology. Urinary Bladder / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12921662.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Xiao ZJ, Li CL: [Diagnosis and treatment of malignant bladder non-epithelial tumors]. Zhonghua Yi Xue Za Zhi; 2008 Nov 4;88(40):2845-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of malignant bladder non-epithelial tumors].
  • OBJECTIVE: To study the clinical diagnosis, treatment, and prognosis of malignant bladder non-epithelial tumors.
  • METHODS: The clinical data of 17 cases with malignant bladder non-epithelial tumor, 15 males and 3 females, aged 28 (3-73), were analyzed.
  • RESULTS: Ten of the 17 cases were diagnosed as with rhabdomyosarcoma, 2 with malignant lymphoma, and 2 with malignant pheochromocytoma, 2 with leiomyosarcoma, and 1 with carcinosarcoma.
  • All patients underwent operation, or were treated with radiotherapy or chemotherapy.
  • Two patients with malignant lymphoma underwent partial cystectomy and adjuvant radiotherapy or chemotherapy, and survived for more than 3 years.
  • Of the 2 cases with malignant pheochromocytoma, one underwent lymphadenectomy and adjuvant chemotherapy and survived for more than 5 years; and another case died 2 years after operation and chemotherapy.
  • Two patients with leiomyosarcoma underwent simple resection, one survived for more than 5 years; and another survived 1 year after operation.
  • One case with carcinosarcoma receiving operation followed by chemotherapy died in one year.
  • CONCLUSION: Malignant bladder non-epithelial tumors are rare clinically and most of them occur in children.
  • The prognosis of malignant bladder non-epithelial tumors, different in pathological types, is relatively worse in adults.
  • [MeSH-major] Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080495.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Gupta NP, Ansari MS, Khaitan A, Dawar R: Fertility preserving radical cystectomy in a young female with malignant mesenchymal tumour of urinary bladder. Int Urol Nephrol; 2003;35(4):501-2
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility preserving radical cystectomy in a young female with malignant mesenchymal tumour of urinary bladder.
  • Fertility preserving radical cystectomy has been reported in young males with leiomyosarcoma and transitional cell carcinoma but not in females.
  • We present a case of 19-year-old lady with mesenchymal tumour of urinary bladder with myogenic differentiation who was managed with fertility preserving radical cystectomy.
  • Adjuvant chemotherapy (Ifosfamide, CDDP and Etocid) was given.
  • [MeSH-major] Cystectomy / methods. Fertility. Sarcoma / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Female. Humans. Mesenchymal Stromal Cells / pathology. Treatment Outcome. Urinary Diversion. Urologic Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1999 Jun;161(6):1761-4 [10332430.001]
  • [Cites] J Urol. 2001 Jan;165(1):51-5; discussion 55 [11125362.001]
  • [Cites] Int J Gynecol Cancer. 1999 Jul;9(4):302-306 [11240783.001]
  • (PMID = 15198154.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Torres Lobatón A, Cruz Ortiz H, Rojo Herrera G, Avila Medrano L: [Sarcomas of the vulva. Report of 2 cases]. Ginecol Obstet Mex; 2000 Oct;68:429-34
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first case was a teenager of 14 years-old with a low grade leiomyosarcoma surgically treated.
  • Along a 22 years follow-up the disease has had four local recurrences of more than 5 cm each one: two after surgery and two after surgery plus chemotherapy and surgery plus radiotherapy respectively.
  • She is alive disease evidence after two years from the last combined treatment.
  • The second one, was a 26 years-old patient with a malignant schwannoma of 12 cm in diameter treated with combined radical surgery, radiotherapy, and chemotherapy.
  • Treatment of vulvar sarcomas is radical local excision followed mainly by radiotherapy with infiltrating margins.
  • The value of postoperative adjuvant chemotherapy is uncertain.
  • According to the natural history and behavior of vulvar sarcomas, we conclude that the elective treatment of these tumors should be carry out in institutions of high level.
  • [MeSH-major] Leiomyosarcoma. Neurilemmoma. Vulvar Neoplasms
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / radiotherapy. Abdominal Neoplasms / secondary. Adolescent. Adult. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bartholin's Glands. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cystectomy. Cysts / diagnosis. Dacarbazine / administration & dosage. Dacarbazine / therapeutic use. Diagnosis, Differential. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / secondary. Radioisotope Teletherapy. Retrospective Studies. Treatment Outcome. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11138405.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 12
  •  go-up   go-down


20. Méndez R, Arnáiz S, Montero M, Tellado M, País E, Ríos J, Vela D: [Clinical patterns of soft-tissue sarcoma in children]. Cir Pediatr; 2001 Jan;14(1):14-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical patterns of soft-tissue sarcoma in children].
  • INTRODUCTION AND OBJECTIVES: Soft tissue sarcomas are rare mesenchymal neoplasms that constitute less than 10% of all pediatric malignancies.
  • Half of these are rhabdomyosarcomas, the remaining 50% have a varied and heterogenous histologic and clinical patterns (fibrosarcoma, synovial cell sarcoma, extraskeletal Ewing's sarcoma, angiosarcoma, liposarcoma, leiomyosarcoma, ...).
  • The purpose of this work is to evaluate our clinical experience with soft tissue sarcomas in uncommon sites over the past 10 years in order to delimitate the prognostic factors in survival and modalities of treatment.
  • MATERIAL AND METHODS: Between 1989 and 1998, 10 patients were diagnosed with soft tissue sarcomas in uncommon sites and treated by us over a total number of 139 pediatric neoplasms (7.19%).
  • Variables investigated included histologic findings, tumor size, age at presentation, primary site, clinical group, radiologic test performed, surgical treatment, radiotherapy and adjuvant chemotherapy, complications and survival rates.
  • RESULTS: The following histologic types of these 10 tumors were identified: 1 hemangiopericytoma in oral cavity, 2 extraosseous Ewing's sarcoma, 1 botryoid rhabdomyosarcoma of the bladder, 1 mediastinal fibrosarcoma, 1 retroperitoneal rhabdomyosarcoma, 1 paratesticular rhabdomyosarcoma, 1 cervical condrosarcoma, 1 alveolar rhabdomyosarcoma and 1 deltoid rhabdomyosarcoma.
  • The mean age at diagnosis was 7 years (4.6 years accounted for rhabdomyosarcoma alone).
  • Adjuvant chemotherapy with IVA was followed by radiotherapy only in four patients.
  • All the children classified in clinical groups II, III or IV needed 2nd. line regimens of chemotherapy.
  • Three patients died in the follow-up instead of the multimodal treatment.
  • 2) radiotherapy will only be necessary if margins of resection cannot control the local disease, and 3) chemotherapy have not clearly demonstrated his benefits as adjuvant therapy in clinical group I lesions but his employ is recommended in all cases because of the poor prognosis due to local recurrence.
  • [MeSH-major] Sarcoma / therapy. Soft Tissue Neoplasms / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11339112.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


21. Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, Gomez J, Guzmán C, Jimeno J, Hanauske A: Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer; 2003 Sep;39(13):1842-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One pCR (melanoma), CR (uterine leiomyosarcoma), one PR (colon stromal sarcoma) and a MR (37% tumour shrinkage, gastric stromal sarcoma) were observed.
  • A further 9 patients with colorectal, mesothelioma, bile duct carcinoma and bladder cancer had SD which lasted for six or more treatment cycles.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacokinetics. Dioxoles / pharmacokinetics. Isoquinolines / pharmacokinetics. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Dose-Response Relationship, Drug. Female. Hematologic Diseases / chemically induced. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Tetrahydroisoquinolines

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12932661.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  •  go-up   go-down


22. Caceres A, Mourton SM, Bochner BH, Gerst SR, Liu L, Alektiar KM, Kardos SV, Barakat RR, Boland PJ, Chi DS: Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1139-44
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor histology was as follows: adenocarcinoma, seven; squamous cell carcinoma, three; leiomyosarcoma, three; and adenosarcoma, one.
  • Previous treatment included hysterectomy, 11; pelvic radiation, 9; chemotherapy, 9; and total pelvic exenteration, 2.
  • Seven patients (50%) received high-dose rate intraoperative radiation therapy.
  • Median total operating time was 628 min (range, 345-935 min) and median estimated blood loss was 900 mL (range, 300-16,000 mL).
  • Seven patients (50%) had one or more major complication(s), including pelvic abscess, three; colonic fistula, two; massive intraoperative hemorrhage, one; postoperative bladder perforation, one; thrombosed femoral-femoral graft, one; and disruption of appendicocutaneous urinary anastomosis, one.






Advertisement